Posted by Michael Wonder on 22 Nov 2021
bluebird bio Announces FDA priority review of biologics license application for beti-cel gene therapy for patients with β-thalassemia who require regular red blood cell transfusions
22 November 2021 - FDA set PDUFA date of 20 May 2022.
bluebird bio today announced that the U.S. FDA has accepted the biologics license application for betibeglogene autotemcel for priority review.
